Annual Report

Overview

The report presents Piramal Pharma's FY2023 ESG progress under a four-pillar, 12-focus-area framework with more than 50 time-bound targets. It reports 27,163 tCO2e of Scope 1 and 58,404 tCO2e of Scope 2 emissions, alongside 7,62,820 GJ of total energy consumption and 10,100 metric tonnes of waste. The global workforce totaled 6,295 employees, while women represented 30% of the Board. The report also includes a BRSR covering ESG governance, human rights, health and safety, energy, water, emissions and waste.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022-2023
Period: 1 April 2022 – 31 March 2023
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

SBTi status

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services

Overview